Menu
Search
|

Menu

Close
X

Apricus Biosciences Inc APRI.OQ (NASDAQ Stock Exchange Capital Market)

0.30 USD
-0.00 (-0.00%)
As of Nov 20
chart
Previous Close 0.30
Open 0.30
Volume 26,275
3m Avg Volume 122,877
Today’s High 0.30
Today’s Low 0.29
52 Week High 3.34
52 Week Low 0.25
Shares Outstanding (mil) 28.17
Market Capitalization (mil) 9.26
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
5
EPS (USD)
FY18
-0.358
FY17
-1.066
FY16
-1.264
FY15
-3.848
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.34
Price to Sales (TTM)
vs sector
--
20.58
Price to Book (MRQ)
vs sector
2.25
4.23
Price to Cash Flow (TTM)
vs sector
--
21.19
Total Debt to Equity (MRQ)
vs sector
0.00
13.84
LT Debt to Equity (MRQ)
vs sector
0.00
9.93
Return on Investment (TTM)
vs sector
-178.70
13.58
Return on Equity (TTM)
vs sector
-190.97
15.11

EXECUTIVE LEADERSHIP

Kleanthis Xanthopoulos
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Richard Pascoe
Chief Executive Officer, Principal Accounting Officer, Secretary, Director, Since 2016
Salary: $473,200.00
Bonus: $88,555.00
Paul Maier
Independent Director, Since 2012
Salary: --
Bonus: --
Rusty Ray
Independent Director, Since 2013
Salary: --
Bonus: --
Sandford Smith
Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11975 El Camino Real Ste 300
SAN DIEGO   CA   92130-2543

Phone: +1858.2228041

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

SPONSORED STORIES